STOCK TITAN

[SCHEDULE 13G] PALISADE BIO, INC. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G

Perceptive Advisors LLC, its founder Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd. reported beneficial ownership of 12,243,018 shares of Palisade Bio, Inc. common stock, representing 9.99% of the class on a fully considered basis. The calculation uses 96,645,431 reported outstanding shares plus 25,714,285 shares from the underwriters' over-allotment and assumes exercise of Pre-Funded Warrants for 193,018 shares permitted under a stated Beneficial Ownership Limitation. The Master Fund directly holds 12,050,000 shares and 5,185,714 Pre-Funded Warrants, and Perceptive Advisors acts as investment manager; Mr. Edelman is the managing member. The filing states the position was not acquired to influence control.

Perceptive Advisors LLC, il suo fondatore Joseph Edelman e Perceptive Life Sciences Master Fund, Ltd. hanno riportato la titolarità beneficiaria di 12.243.018 azioni ordinarie di Palisade Bio, Inc., rappresentando 9,99% della categoria su base completamente ponderata. Il calcolo utilizza 96.645.431 azioni in circolazione riportate piú 25.714.285 azioni dall'over-allotment degli underwriter e presuppone l'esercizio di Pre-Funded Warrants per 193.018 azioni consentite sotto una specifica Limitazione di Beneficial Ownership. Il Master Fund detiene direttamente 12.050.000 azioni e 5.185.714 Pre-Funded Warrants, e Perceptive Advisors agisce come gestore degli investimenti; il signor Edelman è il membro gestore. La documentazione afferma che la posizione non è stata acquistata per influire sul controllo.

Perceptive Advisors LLC, su fundador Joseph Edelman y Perceptive Life Sciences Master Fund, Ltd. reportaron la titularidad beneficiosa de 12.243.018 acciones comunes de Palisade Bio, Inc., que representan 9,99% de la clase en base totalmente ponderada. El cálculo usa 96.645.431 acciones en circulación reportadas más 25.714.285 acciones provenientes de la sobreasignación de los underwriters y supone el ejercicio de las Warrants Pre-Funded para 193.018 acciones permitidas bajo una Limitación de Propiedad Beneficiaria especificada. El Master Fund posee directamente 12.050.000 acciones y 5.185.714 Warrants Pre-Funded, y Perceptive Advisors actúa como administrador de inversiones; el Sr. Edelman es el miembro gerente. La presentación indica que la posición no fue adquirida para influir en el control.

Perceptive Advisors LLC의 설립자 Joseph EdelmanPerceptive Life Sciences Master Fund, Ltd.는 Palisade Bio, Inc.의 보통주 중 12,243,018주에 대한 유용 소유권을 보고했으며, 이는 클래스의 9.99%에 해당합니다. 계산은 96,645,431주가 보고된 발행주식에 더해 25,714,285주가 언더라이더의 초과배정에서 추가되며 명시된 유용 소유 한도 내에서 허용되는 193,018주의 Pre-Funded Warrants의 행사를 가정합니다. Master Fund는 직접 12,050,000주와 5,185,714의 Pre-Funded Warrants를 보유하며, Perceptive Advisors는 투자 관리자로 활동합니다; Mr. Edelman은 매니징 멤버입니다. 제출서는 이 포지션이 지배력을 확보하기 위한 것이 아니라고 명시합니다.

Perceptive Advisors LLC, son fondateur Joseph Edelman et Perceptive Life Sciences Master Fund, Ltd. ont déclaré la propriété bénéficiaire de 12 243 018 actions ordinaires de Palisade Bio, Inc., représentant 9,99% de la classe sur une base pleinement prise en compte. Le calcul utilise 96 645 431 actions en circulation signalées plus 25 714 285 actions provenant de l'over-allocation des souscripteurs et suppose l'exercice des Pre-Funded Warrants pour 193 018 actions autorisées sous une Limite de Propriété Bénéficiaire précisée. Le Master Fund détient directement 12 050 000 actions et 5 185 714 Pre-Funded Warrants, et Perceptive Advisors agit en tant que gestionnaire d'investissement; M. Edelman est le membre gérant. Le dépôt indique que la position n'a pas été acquise dans le but d'influencer le contrôle.

Perceptive Advisors LLC, sein Gründer Joseph Edelman und Perceptive Life Sciences Master Fund, Ltd. haben einen wirtschaftlich berechtigten Anteil an 12.243.018 Stammaktien von Palisade Bio, Inc. gemeldet, was 9,99% der Klasse auf einer voll berücksichtigten Basis entspricht. Die Berechnung verwendet 96.645.431 berichtete umlaufende Aktien zuzüglich 25.714.285 Aktien aus dem Over-Allotment der Underwriter und geht von der Ausübung von Pre-Funded Warrants für 193.018 Aktien aus, die unter einer angegebenen Beneficial Ownership Limitation zulässig sind. Der Master Fund hält direkt 12.050.000 Aktien und 5.185.714 Pre-Funded Warrants, und Perceptive Advisors fungiert als Investmentmanager; Herr Edelman ist das managing member. Die Einreichung erklärt, dass die Position nicht dazu bestimmt war, die Kontrolle zu beeinflussen.

Perceptive Advisors LLC، مؤسسها Joseph Edelman وPerceptive Life Sciences Master Fund, Ltd. أبلغوا عن ملكية مفيدة لـ 12,243,018 سهماً عادياً في Palisade Bio, Inc.، مما يمثل 9,99% من الفئة على أساس محسوب بالكامل. يحسب الاستدلال باستخدام 96,645,431 سهمًا قائمًا وفقًا للإبلاغ بالإضافة إلى 25,714,285 سهمًا من تخصيص المنح من قبل المراسلين ويفترض تمكين ممارسة Pre-Funded Warrants لــ 193,018 سهمًا الم سموح به بموجب قيد الملكية المستفيدة المحدد. الصندوق الرئيسي يحتفظ بشكل مباشر بـ 12,050,000 سهم و 5,185,714 من Pre-Funded Warrants، وتتصرف Perceptive Advisors كمدير للاستثمار؛ السيد Edelman هو العضو المدير. يذكر الملف أن المركز لم يتم الحصول عليه من أجل التأثير على السيطرة.

Perceptive Advisors LLC, 其创始人 Joseph EdelmanPerceptive Life Sciences Master Fund, Ltd. 报告对 Palisade Bio, Inc. 普通股的受益所有权为 12,243,018 股,约占全体类别的 9.99% 以全面计量的基础。该计算使用已报告的在外流通股数 96,645,431 股,加上来自承销商超额配售的 25,714,285 股,并假设在明确的受益所有权限制下行使 193,018 股的预先授权认股权证。主基金直接持有 12,050,000 股和 5,185,714 的 Pre-Funded Warrants,Perceptive Advisors 充当投资经理;Edelman 先生是管理成员。备案文件表示,该头寸并非为影响控制权而取得。

Positive
  • Material stake disclosed: Combined ownership of 12,243,018 shares representing 9.99%
  • Regulatory compliance: Timely Schedule 13G filing with clear breakdown of direct holdings and warrants
  • Structured warrant limit: Beneficial Ownership Limitation prevents accidental ownership above 9.99%
Negative
  • Near-threshold concentration: Position sits immediately below the 10% level, which could limit future automatic exercises
  • Shared voting/dispositive power only: Reported sole voting and dispositive power are 0, indicating decisions are not claimed as sole control

Insights

Large passive stake disclosed just below the 10% regulatory threshold.

The filing shows a coordinated reporting group holding 12,243,018 shares, equal to 9.99%, which is material for investors because it signals a significant concentrated position without crossing the 10% reporting/beneficial ownership trigger. The position combines direct shares and Pre-Funded Warrants limited by a Beneficial Ownership Limitation that caps exercisable warrants at 193,018 shares.

This structure means further automatic exercise into additional shares is constrained unless circumstances change; monitor any changes to the Beneficial Ownership Limitation or subsequent filings for increases in ownership or changes in voting/dispositive power within the next few reporting cycles, including any amendments or Schedule 13D filings if intentions shift.

Perceptive Advisors LLC, il suo fondatore Joseph Edelman e Perceptive Life Sciences Master Fund, Ltd. hanno riportato la titolarità beneficiaria di 12.243.018 azioni ordinarie di Palisade Bio, Inc., rappresentando 9,99% della categoria su base completamente ponderata. Il calcolo utilizza 96.645.431 azioni in circolazione riportate piú 25.714.285 azioni dall'over-allotment degli underwriter e presuppone l'esercizio di Pre-Funded Warrants per 193.018 azioni consentite sotto una specifica Limitazione di Beneficial Ownership. Il Master Fund detiene direttamente 12.050.000 azioni e 5.185.714 Pre-Funded Warrants, e Perceptive Advisors agisce come gestore degli investimenti; il signor Edelman è il membro gestore. La documentazione afferma che la posizione non è stata acquistata per influire sul controllo.

Perceptive Advisors LLC, su fundador Joseph Edelman y Perceptive Life Sciences Master Fund, Ltd. reportaron la titularidad beneficiosa de 12.243.018 acciones comunes de Palisade Bio, Inc., que representan 9,99% de la clase en base totalmente ponderada. El cálculo usa 96.645.431 acciones en circulación reportadas más 25.714.285 acciones provenientes de la sobreasignación de los underwriters y supone el ejercicio de las Warrants Pre-Funded para 193.018 acciones permitidas bajo una Limitación de Propiedad Beneficiaria especificada. El Master Fund posee directamente 12.050.000 acciones y 5.185.714 Warrants Pre-Funded, y Perceptive Advisors actúa como administrador de inversiones; el Sr. Edelman es el miembro gerente. La presentación indica que la posición no fue adquirida para influir en el control.

Perceptive Advisors LLC의 설립자 Joseph EdelmanPerceptive Life Sciences Master Fund, Ltd.는 Palisade Bio, Inc.의 보통주 중 12,243,018주에 대한 유용 소유권을 보고했으며, 이는 클래스의 9.99%에 해당합니다. 계산은 96,645,431주가 보고된 발행주식에 더해 25,714,285주가 언더라이더의 초과배정에서 추가되며 명시된 유용 소유 한도 내에서 허용되는 193,018주의 Pre-Funded Warrants의 행사를 가정합니다. Master Fund는 직접 12,050,000주와 5,185,714의 Pre-Funded Warrants를 보유하며, Perceptive Advisors는 투자 관리자로 활동합니다; Mr. Edelman은 매니징 멤버입니다. 제출서는 이 포지션이 지배력을 확보하기 위한 것이 아니라고 명시합니다.

Perceptive Advisors LLC, son fondateur Joseph Edelman et Perceptive Life Sciences Master Fund, Ltd. ont déclaré la propriété bénéficiaire de 12 243 018 actions ordinaires de Palisade Bio, Inc., représentant 9,99% de la classe sur une base pleinement prise en compte. Le calcul utilise 96 645 431 actions en circulation signalées plus 25 714 285 actions provenant de l'over-allocation des souscripteurs et suppose l'exercice des Pre-Funded Warrants pour 193 018 actions autorisées sous une Limite de Propriété Bénéficiaire précisée. Le Master Fund détient directement 12 050 000 actions et 5 185 714 Pre-Funded Warrants, et Perceptive Advisors agit en tant que gestionnaire d'investissement; M. Edelman est le membre gérant. Le dépôt indique que la position n'a pas été acquise dans le but d'influencer le contrôle.

Perceptive Advisors LLC, sein Gründer Joseph Edelman und Perceptive Life Sciences Master Fund, Ltd. haben einen wirtschaftlich berechtigten Anteil an 12.243.018 Stammaktien von Palisade Bio, Inc. gemeldet, was 9,99% der Klasse auf einer voll berücksichtigten Basis entspricht. Die Berechnung verwendet 96.645.431 berichtete umlaufende Aktien zuzüglich 25.714.285 Aktien aus dem Over-Allotment der Underwriter und geht von der Ausübung von Pre-Funded Warrants für 193.018 Aktien aus, die unter einer angegebenen Beneficial Ownership Limitation zulässig sind. Der Master Fund hält direkt 12.050.000 Aktien und 5.185.714 Pre-Funded Warrants, und Perceptive Advisors fungiert als Investmentmanager; Herr Edelman ist das managing member. Die Einreichung erklärt, dass die Position nicht dazu bestimmt war, die Kontrolle zu beeinflussen.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Perceptive Advisors LLC
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:10/09/2025
Joseph Edelman
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman
Date:10/09/2025
Perceptive Life Sciences Master Fund, Ltd.
Signature:/s/ Joseph Edelman
Name/Title:Joseph Edelman, Managing Member
Date:10/09/2025

FAQ

What stake did Perceptive report in Palisade Bio (PALI)?

Perceptive Advisors, Joseph Edelman and Perceptive Life Sciences Master Fund reported beneficial ownership of 12,243,018 shares, equal to 9.99%.

How is the 9.99% ownership percentage calculated?

The percentage is based on 96,645,431 outstanding shares reported by the issuer plus 25,714,285 over-allotment shares and assumes exercise of Pre-Funded Warrants for 193,018 shares permitted under the Beneficial Ownership Limitation.

Does the filing indicate control of Palisade Bio?

No; the certifying statement says the securities were not acquired to change or influence control, and each Reporting Person reports 0 sole voting power and 0 sole dispositive power.

What are the Pre-Funded Warrants disclosed?

The Master Fund directly holds 5,185,714 Pre-Funded Warrants exercisable for common stock at $0.0001 per share, subject to the Beneficial Ownership Limitation which currently permits exercise for up to 193,018 shares.

Who signs the Schedule 13G for these filings?

The Schedule is signed by Joseph Edelman as Managing Member of Perceptive Advisors and on behalf of the Master Fund, dated 10/09/2025.
Palisade Bio Inc

NASDAQ:PALI

PALI Rankings

PALI Latest News

PALI Latest SEC Filings

PALI Stock Data

245.12M
96.62M
0.24%
5.92%
3.6%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
CARLSBAD